Bone Care International Announces Appointment of New Directors.Business Editors MIDDLETON, Wis.--(BUSINESS WIRE)--Nov. 19, 2001 Bone Care International, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BCII BCII Battle Command and Intelligence Integration ) announced today the appointment of two new directors to its Board. Michael D. Casey has been elected to a three-year term ending in 2004. Mr. Casey, who is Chairman of the Board, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Matrix Pharmaceutical, has extensive pharmaceutical background, having served as President of McNeil Pharmaceutical, a division of Johnson & Johnson, in the early 1990s and as President of the retail and specialty products division of Schein Pharmaceutical prior to joining Matrix Pharmaceutical. Edward N. Staiano, Chairman and Chief Executive Officer of Sorrento Investment Group, has been appointed to a two-year term to replace Charles W. Bishop, former President of Bone Care. Dr. Bishop remains Executive Vice-President of Research and Development at the company. Prior to starting Sorrento Investment group, Mr. Staiano was the Chairman and CEO of Iridium iridium (ĭrĭd`ēəm), metallic chemical element; symbol Ir; at. no. 77; at. wt. 192.22; m.p. about 2,410°C;; b.p. about 4,130°C;; sp. gr. 22.55 at 20°C;; valence +3 or +4. World Communications Limited. Mr. Staiano joined Iridium following a 23-year career with Motorola, where he headed the cellular business in the 1980s and was President of the General Systems Sector before retiring from Motorola in 1996. Dr. Richard B. Mazess, Chairman and Acting-President, said that the current appointments are part of Bone Care's plan to expand the number of outside directors. "I am pleased and honored to welcome these two highly experienced executives to the Bone Care Board of Directors," commented Dr. Mazess. "Along with the existing board members, I am confident in their ability to help select our new president and provide the necessary leadership that will enable Bone Care to take full advantage of its opportunities." Bone Care is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism secondary hyperparathyroidism Endocrinology ↑ Parathyroid activity with overproduction of PTH due to parathyroid hyperplasia in response to an extraparathyroid defect that results in ↓ Ca2+ Etiology Rickets, vitamin D deficiency, chronic renal failure in patients with kidney, or renal disease Renal disease Kidney disease. Mentioned in: Glycogen Storage Diseases hypertension High blood pressure Cardiovascular disease An abnormal ↑ systemic arterial pressure, corresponding to a systolic BP of > 160 mm Hg , and osteoporosis, and other diseases including psoriasis psoriasis (sôrī`əsĭs), occasionally acute but usually chronic and recurrent inflammation of the skin. The exact cause is unknown, but the disease appears to be an inherited, possibly autoimmune disorder that causes the and cancers of the prostate, breast and colon. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion